Skip to main content
. 2017 Oct 25;9:655–668. doi: 10.2147/CEOR.S136657

Table S1.

Drug acquisition costs

Product Dosage Price per package (including all taxes) (EUR) Dispensing fee (EUR) Monthly treatment cost (EUR)
Compared treatments
Afatinib (GIOTRIF®; Boehringer Ingelheim, Ingelheim, Germany)
40 mg; 28 tablets
CIP: 3400927565878
40 mg/day orally 1,870.48 1.02/pack 2,033.04
Erlotinib (TARCEVA®; Roche, Basel, Switzerland)
150 mg; 30 tablets
CIP: 3400936923522
150 mg/day orally 2,071.92 1.02/pack 2.072.94
Post-progression treatments for additional sensitivity analyses
Nivolumab (OPDIVO®; Bristo-Myers Squibb, New York, NY, USA)
10 mg/mL; vial of 10 mL*
3 mg/kg every 2 weeks intravenously until death 1,344.33 N/A 8,757.66
Docetaxel 75 mg/m2 every 3 weeks intravenously Cost included in DRG cost Cost included in DRG cost Cost included in DRG cost
Paclitaxel 200 mg/m2 every 3 weeks intravenously Cost included in DRG cost Cost included in DRG cost Cost included in DRG cost
Best supportive care N/A N/A N/A N/A

Note:

*

UK cost estimated in euros using an exchange rate of 1.19474 (July 2016).

Abbreviations: CIP, Club Inter Pharmaceutique (ID code for pharmaceuticals in France); DRG, diagnosis-related group; N/A, not applicable.